• Loading stock data…

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

Last Updated on May 18, 2023 by


Print Friendly, PDF & Email
Spread the word

Reader Interactions

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Generated by Feedzy
%d bloggers like this: